2026-07-21T14:00:53Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/173532024-01-23T20:13:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Peta, Valentina
author
Tse, Chantal
author
Perazzo, Hugo
author
Munteanu, Mona
author
Ngo, Yen
author
Ngo, An
author
Ramanujam, Nittia
author
Verglas, Lea
author
Mallet, Maxime
author
Ratziu, Vlad
author
Thabut, Dominique
author
Rudler, Marika
author
Thibault, Vincent
author
Schuppe-Koistinen, Ina
author
Bonnefont-Rousselot, Dominique
author
Hainque, Bernard
author
Imbert-Bismut, Françoise
author
Merz, Michael
author
Kullak-Ublick, Gerd
author
Andrade, Raul
author
van Boemmel, Florian
author
Schott, Eckart
author
Poynard, Thierry
author
Drug Induced Liver Injury- Groupe Hospitalier Pitié-Salpêtrière
author
Drug Induced Liver Group of the Injury Safer and Faster Evidence-based Translation consortium
2024-01-23T20:13:25Z
2024-01-23T20:13:25Z
2017-12-29
10.1371/journal.pone.0189436
1932-6203
PloS one
http://hdl.handle.net/10668/11960
29287080
http://hdl.handle.net/20.500.12105/17353
There is a clear need for better biomarkers of drug-induced-liver-injury (DILI). We aimed to evaluate the possible prognostic value of ActiTest and FibroTest proteins apoliprotein-A1, haptoglobin and alpha-2-macroglobulin, in patients with DILI. We analyzed cases and controls included in the IMI-SAFE-T-DILI European project, from which serum samples had been stored in a dedicated biobank. The analyses of ActiTest and FibroTest had been prospectively scheduled. The primary objective was to analyze the performance (AUROC) of ActiTest components as predictors of recovery outcome defined as an ALT After adjudication, 154 patients were considered to have DILI and 22 were considered to have acute liver injury without DILI. A multivariate regression analysis (ActiTest-DILI patent pending) combining the ActiTest components without BILI and ALT (used as references), apolipoprotein-A1, haptoglobin, alpha-2-macroglobulin and GGT, age and gender, resulted in a significant prediction of recovery with 67.0% accuracy (77/115) and an AUROC of 0.724 (P We identified that apolipoprotein-A1 and haptoglobin had significant predictive values for the prediction of recovery at 12 weeks in DILI, enabling the construction of a new prognostic panel, the DILI-ActiTest, which needs to be independently validated.
eng
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
research article